TransDigm Group is caught in an unusual tension: options traders have turned their most bullish in months, yet short sellers are quietly rebuilding positions into a stock that has lost more than 13% over the past month.
The options signal is the week's clearest outlier. The put/call ratio dropped to 0.85 on Monday — more than two standard deviations below its 20-day average of 1.20. That makes it the most call-heavy reading in recent memory, a sharp reversal from the deeply defensive posture that prevailed through August, when the PCR ran as high as 1.64. The shift is striking given the stock's continued slide; traders appear to be positioning for a recovery rather than hedging against further losses.
Short interest tells a more cautious story on the other side of the ledger. Bears added roughly 15% to their positions over the past week, pushing short interest to about 1.7% of the free float — still low in absolute terms, but the pace of rebuild is notable. Cost to borrow doubled week-on-week to 0.60%, though at that level the lending market remains wide open. Availability is exceptional at roughly 8,600%, meaning the borrow pool dwarfs current short demand by an enormous margin. This is not a squeeze setup; it reads more like a measured tactical short being layered in during the selloff, with ample room to grow.
The analyst community is divided, and the recent moves reflect that split. Guggenheim initiated coverage this week with a Neutral, adding to a consensus that leans Hold — nine buys against eleven holds, with a mean price target near $1,515 against a current price of $1,085. That gap implies over 39% upside to the Street median, though that number should be read carefully: Morgan Stanley cut its target to $1,345 in July and moved to Equal-Weight, while Stifel downgraded to Hold in August after the last earnings print. UBS remains the most constructive, holding Buy with a $1,695 target raised after Q3 results. The bull case rests on commercial aftermarket momentum and 160 basis points of year-on-year margin expansion in OE. The bear case is harder to dismiss: FY2026 EBITDA guidance was set at $5.15 billion, below consensus, with projected margin erosion of 140 basis points tied to the Simmonds acquisition dilution and a weaker product mix. On valuation, the EV/EBITDA multiple has compressed to around 15x, down roughly 0.4 turns over the past month, reflecting the re-rating pressure. EPS momentum factor scores are modestly positive at 52-59 percentile, but the value pillar remains weak by design — TDG has always been a quality-growth name, not a value play.
Institutional ownership adds one genuinely interesting note. The Vanguard Group filed a 13G/A in March disclosing it had exited a position that previously stood at 11.9% of shares. Separately, Vanguard Capital Management filed a fresh 13G in April showing a 7.48% stake, and Capital International Investors disclosed 9.9% in May. These are passive disclosures, not activist positions — no 13D is on the register — but the restructuring of what was a dominant Vanguard position is worth tracking as index-weight mechanics play out. On the insider side, director W. Nicholas Howley executed a cluster of pre-planned 10b5-1 sales on August 18 totaling approximately $4.6 million in gross proceeds, offset by option exercises. All trades were under a scheduled plan, reducing their signal value materially.
Peers were similarly weak on the week. HEICO fell 6.1% and GE Aerospace dropped 8.3%, suggesting sector-wide pressure rather than a TDG-specific catalyst. RTX held up better, off just 1.7%, while VSEC had the worst week in the group at -13.9%. The next scheduled catalyst for TDG is the Q4 earnings release on November 10 — the last print delivered a 2.4% one-day decline and a 3.4% five-day loss, so how the company addresses the guidance miss and acquisition integration will be the central question when that date arrives.
See the live data behind this article on ORTEX.
Open TDG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
